A retrospective case series of patients who self-medicated with Famotidine during coronavirus disease 2019 (COVID-19). The study will collect de-identified patient reported outcome measures of patients with confirmed COVID-19 who self-medicated with Famotidine at any dose during the period of illness. Data will be collected by questionnaire and telephone interview. Inclusion criteria: Age>18; Ability to give written informed consent for study participation; Confirmed diagnosis of COVID-19; Use of Famotidine at any dose during period of COVID-19 illness
Famotidine is a histamine-2 receptor antagonist, widely available over-the-counter, and is
safely used for suppression of gastric acid production over a wide range of doses from 20mg
once daily to 160mg four times daily. In computer-based simulations, Famotidine has been
identified as a potential inhibitor of the 3-chymotrypsin-like protease (3CLpro). In a
propensity score matched retrospective cohort study a significantly reduced risk for death or
intubation (adjusted hazard ratio 0.43, 95% confidence interval 0.21-0.88) was identified for
patients with COVID-19 who were taking Famotidine before or at the point of hospital
admission. Some individuals have self-medicated with Famotidine while being outpatients with
COVID-19. This study is aimed at collecting patient reported outcome measures from such
individuals.
Drug: Famotidine
Use of oral Famotidine.
Inclusion Criteria:
Age >18 years; Ability to give written informed consent; Confirmed COVID-19 diagnosis;
Famotidine use during COVID-19 illness
Exclusion Criteria:
none
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York, United States
David A Tuveson, MD PhD, Principal Investigator
Cold Spring Harbor Laboratory